Navigation Links
Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
Date:10/1/2008

Intermezzo(R) (zolpidem tartrate sublingual lozenge) developed to be the

first sleep aid specifically for use in the middle of the night when

patients awaken and have difficulty returning to sleep

PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge). Intermezzo(R) is a low dose, buffered, sublingual formulation of zolpidem intended to be the first prescription sleep aid to be indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.

The Intermezzo(R) NDA submission follows the successful completion of two Phase 3 clinical trials. The first Intermezzo(R) Phase 3 trial was a double-blind, placebo-controlled crossover sleep laboratory study of 82 patients, which Transcept believes to be among the largest reported sleep laboratory studies of its type. This objective study demonstrated that the Intermezzo(R) 1.75 mg and 3.5 mg doses, when used at the time of a middle of the night awakening, significantly shortened the time for patients to return to sleep as compared to placebo, and there was no evidence of next day residual sedative effects with either dose. Transcept believes that these are the lowest zolpidem doses that have been reported to be statistically superior to placebo in producing sleep. When patients used the 3.5 mg dose, the study also indicated statistically significant improvements in total sleep time, sleep efficiency, subjective number of post-dose awakenings, sleep quality, level of refreshed sleep, and next day ability to function.

The second Phase 3 clinical trial was a double-blind, placebo-controlled outpatient study in which 294 patients used either In
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Critical Pharmaceuticals Enter Sustained Release hGH Arena
3. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
4. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
9. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
10. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
11. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... N.Y. , Feb. 26, 2015 Every ... more research to fight heart disease.  Nevertheless, year after ... on ElectroCardioGrams (EKG) as the first test to determine ... they have chest pain or not, even though that ... occurs despite the fact that doctors know, (while most ...
(Date:2/26/2015)... Feb. 26, 2015 Research and Markets ... "Radiation Therapy Equipment - Global Strategic Business Report" ... report analyzes the worldwide markets for Radiation Therapy Equipment ... Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator. The ... Canada , Japan , ...
(Date:2/26/2015)... 2015  Spring Bank Pharmaceuticals, Inc., a clinical-stage ... of Hepatitis B virus (HBV) and other viral ... million financing. Funds from this financing will accelerate ... spectrum antiviral agent derived from Spring Bank,s ... platform, into Phase II clinical trials for the ...
Breaking Medicine Technology:National Heart Health Month In February 2Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2Spring Bank Pharmaceuticals Completes $22 Million Financing 2
... standard has replaced the Statement on Auditing Standards No. ... Standards for Attestation Engagements No. 16 (SSAE 16), became ... to enforce a stronger set of controls and more ... Rising Medical Solutions has taken the first ...
... ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today announced ... Global Healthcare Conference in London. Dr. Ramin Mojdeh, Executive ... to present at 5:00 p.m. British Summer Time (12:00 ... The conference presentation will be broadcast over the ...
Cached Medicine Technology:Rising Medical Solutions, an Early Adopter of SAS 70's Replacement Standard 2Rising Medical Solutions, an Early Adopter of SAS 70's Replacement Standard 3Unilife to Present at the Jefferies 2011 Global Healthcare Conference in London 2
(Date:2/27/2015)... According to court documents, Donna Pirolli was a ... and underwent a procedure during which a duodenoscope was ... the duodenoscope allegedly had not been properly cleaned, Donna ... (CRE). , A lawsuit has been proceeding ... of Ms. Pirolli alleging that Lutheran General Hospital was ...
(Date:2/27/2015)... 27, 2015 Adding to its ... pharmaceuticals, Benedict Advertising & Marketing has added Sedation ... The company’s patented NITROUSEAL® N20 closed mask and ... of sedation. , Sedation Systems, http://www.sedationsystems.com ... a new level, though it focuses primarily on ...
(Date:2/27/2015)... The Dawn Greene Hospice, a 10-bed facility ... (MMW) on the Upper East Side, was officially dedicated and ... His Eminence Timothy Michael Cardinal Dolan. , Thomas J. Fahey, ... and a member of the ArchCare Board of Trustees, presided ... O.Carm, executive director of MMW, and Christina McInerney, president and ...
(Date:2/27/2015)... Hospital North Pinellas is being recognized as a Get ... order to receive the award, Florida Hospital North Pinellas ... The Guidelines - Stroke Quality Achievement indicators for two ... higher compliance with six of 10 Get With The ... to measure quality of care. , “Florida ...
(Date:2/27/2015)... Glidewell Laboratories, industry-leading provider of ... its CloudPoint™ family of equipment, software ... monolithic zirconia crowns & bridges, CloudPoint offers dental ... CAD/CAM-produced restorations that doctors demand. Installation of CloudPoint ... can be scanned, managed and produced. After scanning ...
Breaking Medicine News(10 mins):Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3Health News:Florida Hospital North Pinellas Receives Get With The Guidelines - Stroke Gold Plus Quality Achievement Award 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 3
... Researchers say that the advertisement on junk foods shown ... condition on kids by tempting them to go for ... ,According to foodconsumer.org, previous studies have already associated ... is that the link between childhood overweight and TV ...
... with a family history of alcoholism have an enhanced ... who carry no such family history. Now, a recent ... history of alcoholism coupled with behavioral disinhibition run the ... certain that they will become alcoholics. ,William ...
... who work out at the gym should use a towel when ... to reduce the spread// of fungal infections. ,Fungi cause ... hair grows, explains Hans-Juergen Tietz of the Institute for Fungal Illness ... problem as it spreads when it is rubbed off the skin ...
... years have not lessened the pain of losing their ... and his wife Meenakshi to run free counselling// sessions ... ,The Trivedis were shattered when seven-year-old Ammi ... save her, but nothing helped. After her death, the ...
... to the new study it was found that alcoholics who ... prone to commit suicide. This shows the great// impact of ... show that up to 40 % of patients who seek ... 10 times greater than suicide attempts among the general population. ...
... latest study that was lead by Joslin Diabetes Centre ... grow and function. These findings// they hope will help ... ,The Joslin Diabetes Centre in Boston, have conducted a ... the insulin-producing beta cell do not affect in the ...
Cached Medicine News:Health News:Junk Food Ads: The Culprit Behind Childhood Obesity 2Health News:Is Alcoholism Genetic? 2Health News:Distressed Couple Assists Parents Of Mentally Challenged Kids 2Health News:A New study Throws Light On The Growth & Functions Of Insulin Producing Beta Cells 2Health News:A New study Throws Light On The Growth & Functions Of Insulin Producing Beta Cells 3
... durable, the Medelec Synergy N-EP provides ... of a smaller instrument is driven ... take your testing equipment on the ... solution. The 2, 5, or 10-channel ...
Neuropack MEB-2200 evoked potential/EMG measuring system is user friendly Windows NT, Pentium III PC-based EP/EMG measuring system....
Sierra Wave Quickreport eliminates most dictation. Study driven functions make testing faster and easier. Complete 2/4 channel EMG/NCV/EP....
...
Medicine Products: